Keyphrases
Antimicrobial Peptides
40%
Bacterial Inhibition
20%
Bladder
80%
Bladder Microbiome
20%
Catheter
20%
Conjugated Estrogens
20%
Corynebacterium
20%
Culture Protocol
20%
Estrogen
20%
Estrogen Therapy
40%
Estrogen Treatment
60%
Follow-up Data
20%
Growth Inhibition Assay
20%
Lactobacillus
100%
Lactobacillus Dominance
20%
Linear Mixed Model
20%
Menopause
20%
Microbes
20%
Microbial Diversity
40%
Microbiome
80%
New York City
20%
Overactive Bladder Questionnaire
40%
Overactive Bladder Symptom Score (OABSS)
100%
Pelvic Floor
40%
Perineum
20%
Pfizer
20%
Postmenopausal Women
100%
Premarin
20%
Relative Abundance
40%
Symptom Improvement
40%
Symptom Severity
20%
Topical Estrogen
20%
Twice Daily
20%
Urgency Incontinence
20%
Urine Samples
40%
Urobiome
40%
Vaginal Estrogen
20%
Vaginal Estrogen Therapy
100%
Vaginal Microbiome
20%
Vaginal Swab
20%
Voided Urine
40%
Medicine and Dentistry
Bacterial Growth
16%
Bladder
83%
Corynebacterium
16%
Estrogen Therapy
100%
Ethinylestradiol
33%
Growth Inhibition
16%
Incontinence
16%
Lactobacillus
100%
Microbial Diversity
16%
Microbiome
100%
Mixed Model
16%
Overactive Bladder
100%
Overactive Bladder Treatment
16%
Pelvic Floor
33%
Perineum
16%
Polypeptide Antibiotic Agent
33%
Postmenopause
100%
Urinary System
33%
Urine Sampling
33%
Immunology and Microbiology
Antimicrobial Peptides
33%
Bacterial Growth
16%
Corynebacterium
16%
Growth Inhibition
16%
Lactobacillus
100%
Microbial Diversity
16%
Microbiome
100%
Pelvis
33%
Perineum
16%
Postmenopause
100%
Urine Sampling
33%
Vagina
66%
Agricultural and Biological Sciences
Antimicrobial Peptides
16%
Bladder
100%
Conjugated Estrogen
16%
Corynebacterium
8%
Cream
8%
Floors
16%
Lactobacillus
100%
Microbiome
50%
Pelvis
16%
Perineum
8%
Postmenopause
100%
Premarin
8%
Urinary System
16%
Pharmacology, Toxicology and Pharmaceutical Science
Conjugated Estrogen
28%
Corynebacterium
14%
Ethinylestradiol
28%
Incontinence
14%
Lactobacillus
100%
Microbiome
85%
Mixed Model
14%
Overactive Bladder
100%
Polypeptide Antibiotic Agent
28%